Slow Down To Speed Up: US FDA Presses Cases For Dose Optimization
Executive Summary
The US FDA is urging drug companies to abandon traditional approaches to oncology dosing even if it means slowing down early studies. The trade-off should be faster development times overall, FDA says – but sponsors still seem very wary.